

# Annibale Versari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6546834/publications.pdf>

Version: 2024-02-01

122  
papers

4,824  
citations

126907

33  
h-index

102487

66  
g-index

127  
all docs

127  
docs citations

127  
times ranked

5277  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Positron Emission Tomography Responseâ€“Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	1.6	397
2	Omitting Radiotherapy in Early Positron Emission Tomographyâ€“Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1188-1194.	1.6	349
3	Baseline Metabolic Tumor Volume Predicts Outcome in Highâ€“Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 3618-3626.	1.6	231
4	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006, 91, 475-81.	3.5	213
5	Tocilizumab: a novel therapy for patients with large-vessel vasculitis. <i>Rheumatology</i> , 2012, 51, 151-156.	1.9	203
6	Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2017-2022.	6.4	187
7	Clinical features of polymyalgia rheumatica and giant cell arteritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 509-521.	8.0	185
8	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1113-1122.	6.4	152
9	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014, 1, e17-e27.	4.6	138
10	Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 569-580.	6.4	136
11	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018, 131, 1456-1463.	1.4	130
12	Positron emission tomography (PET): Evaluation of chronic periaortitis. <i>Arthritis and Rheumatism</i> , 2005, 53, 298-303.	6.7	128
13	Positron emission tomography in the staging of patients with Hodgkinâ€™s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. <i>Annals of Hematology</i> , 2007, 86, 897-903.	1.8	98
14	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 712-719.	6.4	95
15	Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68Ga-DOTATOC. <i>Nuclear Medicine and Biology</i> , 2008, 35, 721-724.	0.6	93
16	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET Use). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 414-421.	6.4	92
17	Standardization of <sup>18</sup> F-FDGâ€“PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	1.6	85
18	Synthesis and Characterization of <sup>68</sup> Ga-Labeled Curcumin and Curcuminoid Complexes as Potential Radiotracers for Imaging of Cancer and Alzheimerâ€™s Disease. <i>Inorganic Chemistry</i> , 2014, 53, 4922-4933.	4.0	71

#	ARTICLE	IF	CITATIONS
19	State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. <i>Clinical and Translational Imaging</i> , 2021, 9, 299-339.	2.1	70
20	Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients. <i>Thyroid</i> , 2014, 24, 715-726.	4.5	68
21	18F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. <i>Arthritis and Rheumatism</i> , 2005, 53, 122-125.	6.7	65
22	Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. <i>Arthritis Care and Research</i> , 2017, 69, 143-149.	3.4	64
23	Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2010, 35, 321-328.	1.3	62
24	Post-Synthesis Incorporation of <sup>64</sup> Cu in CuS Nanocrystals to Radiolabel Photothermal Probes: A Feasible Approach for Clinics. <i>Journal of the American Chemical Society</i> , 2015, 137, 15145-15151.	13.7	56
25	Rituximab therapy for chronic periaortitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1262-1264.	0.9	53
26	Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2469-2475.	6.7	51
27	Multicenter Comparison of 18F-FDG and 68Ga-DOTA-Peptide PET/CT for Pulmonary Carcinoid. <i>Clinical Nuclear Medicine</i> , 2015, 40, e183-e189.	1.3	51
28	Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1381-1390.	6.4	50
29	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. <i>Blood</i> , 2018, 131, 2449-2453.	1.4	49
30	PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. <i>Tumor Biology</i> , 2014, 35, 8369-8377.	1.8	46
31	Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1074-1082.	3.4	40
32	Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. <i>Rheumatology</i> , 2021, 60, 3851-3861.	1.9	38
33	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e66-e68.	3.5	36
34	Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in) prior use of chemotherapy in routine clinical practice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1102-1110.	6.4	35
35	PET and PET/CT with <sup>68</sup> Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors. <i>Scientific World Journal, The</i> , 2014, 2014, 1-19.	2.1	34
36	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	1.6	34

#	ARTICLE	IF	CITATIONS
37	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , 2015, 54, 2004-2009.	1.9	32
38	Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the <sup>90</sup> Y and <sup>177</sup> Lu labeling conditions. <i>Nuclear Medicine and Biology</i> , 2012, 39, 509-517.	0.6	31
39	<sup>18</sup> F-FDG and <sup>68</sup> Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. <i>EJNMMI Research</i> , 2018, 8, 64.	2.5	28
40	Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1095-1101.	1.1	27
41	Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with <sup>125</sup> I Decay. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1501-1506.	5.0	26
42	Role of Imaging in the Diagnosis of Large and Medium-Sized Vessel Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 593-608.	1.9	24
43	Functional Imaging Evaluation in the Detection, Diagnosis, and Histologic Differentiation of Pulmonary Neuroendocrine Tumors. <i>Thoracic Surgery Clinics</i> , 2014, 24, 285-292.	1.0	24
44	Texture analysis and multiple-instance learning for the classification of malignant lymphomas. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 185, 105153.	4.7	24
45	Influence of different chelators on the radiochemical properties of a <sup>68</sup> -Gallium labelled bombesin analogue. <i>Nuclear Medicine and Biology</i> , 2014, 41, 24-35.	0.6	22
46	Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group 37 study. <i>Hematological Oncology</i> , 2017, 35, 548-553.	1.7	22
47	Added diagnostic value of respiratory-gated 4D <sup>18</sup> F-FDG PET/CT in the detection of liver lesions: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 102-109.	6.4	22
48	Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 776-8.	0.8	22
49	The role of PET/CT in disease activity assessment in patients with large vessel vasculitis. <i>Rheumatology</i> , 2022, 61, 4809-4816.	1.9	22
50	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	1.3	21
51	Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. <i>EJNMMI Physics</i> , 2020, 7, 63.	2.7	21
52	The <sup>68</sup> Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.9	20
53	Standardization of <sup>18</sup> F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	1.4	20
54	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1463-1464.	6.4	19

#	ARTICLE	IF	CITATIONS
55	Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study. <i>Hematological Oncology</i> , 2022, 40, 645-657.	1.7	19
56	Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 875-909.	3.3	17
57	Uptake of Ga-curcumin derivatives in different cancer cell lines: Toward the development of new potential 68 Ga-labelled curcuminoids-based radiotracers for tumour imaging. <i>Journal of Inorganic Biochemistry</i> , 2017, 173, 113-119.	3.5	17
58	Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 99-106.	0.8	17
59	Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 1055.	3.7	17
60	Comparison of Different Positron Emission Tomography Tracers in Patients with Recurrent Medullary Thyroid Carcinoma: Our Experience and a Review of the Literature. <i>Recent Results in Cancer Research</i> , 2013, 194, 385-393.	1.8	16
61	$^{90}\text{Y}$ - and $^{125}\text{I}$ -labelled DOTA-Bioconjugates	0.8	16
62	Affinity of nat/68Ga-Labelled Curcumin and Curcuminoid Complexes for $^{125}\text{I}$ -Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1480.	4.1	15
63	Use of imaging techniques in large vessel vasculitis and related conditions. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 34-39.	0.7	15
64	Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. <i>Journal of Clinical Medicine</i> , 2019, 8, 681.	2.4	15
65	COVID-19 and Parkinson's disease: a casual association or a possible second hit in neurodegeneration?. <i>Journal of Neurology</i> , 2022, 269, 59-61.	3.6	15
66	Chronic Periaortitis. <i>Circulation</i> , 2008, 118, 1214-1216.	1.6	14
67	Partial volume effect of SPECT images in PRRT with 177Lu labelled somatostatin analogues: A practical solution. <i>Physica Medica</i> , 2019, 57, 153-159.	0.7	14
68	18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 30, 593-596.	1.1	14
69	The Role of Imaging in the Diagnosis of Recurrence of Primary Seminal Vesicle Adenocarcinoma. <i>World Journal of Men's Health</i> , 2014, 32, 61.	3.3	13
70	Development of a simple kit-based method for preparation of pharmaceutical-grade 68Ga-DOTATOC. <i>Nuclear Medicine Communications</i> , 2015, 36, 502-510.	1.1	13
71	Detection of a second malignancy in prostate cancer patients by using [18F]Choline PET/CT: a case series. <i>Cancer Imaging</i> , 2016, 16, 27.	2.8	13
72	64Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. <i>Scientific Reports</i> , 2019, 9, 3376.	3.3	13

#	ARTICLE	IF	CITATIONS
73	Semiautomated labelling and fractionation of yttrium-90 and lutetium-177 somatostatin analogues using disposable syringes and vials. <i>Nuclear Medicine Communications</i> , 2012, 33, 1144-1152.	1.1	12
74	Post-ABVD/pre-radiotherapy <sup>18</sup> F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. <i>British Journal of Radiology</i> , 2016, 89, 20150983.	2.2	12
75	Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT. <i>Cancers</i> , 2022, 14, 592.	3.7	12
76	Efficient automated one-step synthesis of 2-[18F]fluoroethylcholine for clinical imaging: optimized reaction conditions and improved quality controls of different synthetic approaches. <i>Nuclear Medicine and Biology</i> , 2010, 37, 309-315.	0.6	11
77	Molecular Imaging of Inflammatory Arthritis and Related Disorders. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 277-290.	4.6	11
78	A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. <i>Clinical Cancer Research</i> , 2020, 26, 373-383.	7.0	11
79	68Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients. <i>Frontiers in Medicine</i> , 2020, 7, 601853.	2.6	11
80	PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. <i>Blood</i> , 2017, 130, 736-736.	1.4	11
81	Personnel exposure in labelling and administration of 177Lu-DOTA-D-Phe1-Tyr3-octreotide. <i>Nuclear Medicine Communications</i> , 2011, 32, 947-953.	1.1	10
82	Clinical images: PET-CT and contrast-enhanced ultrasound in Takayasu's arteritis. <i>Rheumatology</i> , 2014, 53, 447-447.	1.9	10
83	Usefulness of PET in recognizing and managing vasculitides. <i>Current Opinion in Rheumatology</i> , 2018, 30, 24-29.	4.3	10
84	Diagnostic performances of 68Ga-DOTATOC versus 18F-fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 957-960.	1.1	10
85	Radiosynthesis of 68Ga-labelled DOTA-biotin (68Ga-r-BHD) and assessment of its pharmaceutical quality for clinical use. <i>Nuclear Medicine Communications</i> , 2012, 33, 1179-1187.	1.1	9
86	Comparison of different calculation techniques for absorbed dose assessment in patient specific peptide receptor radionuclide therapy. <i>PLoS ONE</i> , 2020, 15, e0236466.	2.5	9
87	Diagnostic performances of [18F]fluorocholine positron emission tomography in brain tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 209-219.	0.7	9
88	The Impact of 18F-deoxyglucose Positron Emission Tomography on Tumor Staging, Treatment Strategy and Treatment Planning for Radiotherapy in a Department of Radiation Oncology. <i>Tumori</i> , 2004, 90, 579-585.	1.1	8
89	Effect of image registration on 3D absorbed dose calculations in 177 Lu-DOTATOC peptide receptor radionuclide therapy. <i>Physica Medica</i> , 2018, 45, 177-185.	0.7	7
90	Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study. <i>RMD Open</i> , 2022, 8, e001977.	3.8	7

#	ARTICLE	IF	CITATIONS
91	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022, 14, 2501.	3.7	7
92	Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012, 120, 1598-1598.	1.4	6
93	Skin dose saving of the staff in 90Y/177Lu peptide receptor radionuclide therapy with the automatic dose dispenser. <i>Nuclear Medicine Communications</i> , 2016, 37, 1046-1052.	1.1	5
94	Severe Rhabdomyolysis during Treatment with Trabectedin in Combination with a Herbal Drug in a Patient with Metastatic Synovial Sarcoma: A Case Report. <i>Case Reports in Oncology</i> , 2017, 10, 258-264.	0.7	5
95	Three-dimensional display of myocardial perfusion detection of ischemic lesions using a new image subtraction method. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1990, 17, 55-60.	2.1	4
96	Pulmonary deposition of aerosolised pentamidine using a new nebuliser: efficiency measurements in vitro and in vivo. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 399-406.	2.1	4
97	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1689-1696.	1.3	4
98	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 18, 419-449.	1.2	4
99	Do we need FDG-PET/CT to assess atherosclerosis?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 247-248.	6.4	3
100	Reply to H.J.A. Adams et al and E. Laffon et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 920-923.	1.6	3
101	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. <i>Clinical and Translational Imaging</i> , 2021, 9, 423-438.	2.1	3
102	Is 18F Fluorodeoxyglucose Positron Emission Tomography Useful to Assess Activity of Myositis?. <i>Journal of Rheumatology</i> , 2013, 40, 91.2-91.	2.0	2
103	Radiation protection procedures in 131I treatments for thyroid cancer in patients requiring hemodialysis. <i>Nuclear Medicine Communications</i> , 2014, 35, 626-630.	1.1	2
104	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. <i>Blood</i> , 2016, 128, 184-184.	1.4	2
105	Impact of PET on the Radiation Treatment of Hodgkins Lymphoma. <i>Current Radiopharmaceuticals</i> , 2009, 2, 169-174.	0.8	2
106	Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome. <i>American Journal of Kidney Diseases</i> , 2017, 70, 725-728.	1.9	1
107	Radiolabeled Somatostatin Analogues in the Treatment of Non-GEP-NET Tumors. , 2018, , 483-503.		1
108	The Role Of Qualitative FDG-PET Assessment Using The 5 Point Deauville Scale For Postinduction Response Assessment In Patients With Follicular Lymphoma. A Study From The Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2013, 122, 4295-4295.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Editorial [Hot Topic: PET & CT AND RADIOTHERAPY (Guest Editors: Diana Salvo, Annibale Versari & Tj ETQq1,10.784314 rgBT	1.0	0
110	Ectopic Mature Cerebral Tissue in the Nasal Cavity Incidentally Detected by 18F-FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, e85-e87.	1.3	0
111	Adding variables to complexity. Molecular imaging and molecular biology: a no-longer-secret liaison in NETs. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1339-1340.	6.4	0
112	FDG-PET and radiotherapy in lymphoma. Clinical and Translational Imaging, 2015, 3, 321-330.	2.1	0
113	THU0599&...RESOLUTION OF VASCULAR INFLAMMATION& IN PATIENTS WITH GIANT CELL ARTERITIS RECEIVING GLUCOCORTICOIDS, METHOTREXATE OR TOCILIZUMAB TREATMENT-DATA FROM THE ITALIAN/GERMAN RIGA STUDY. , 2019, , .		0
114	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Expert Opinion on Pharmacotherapy, 2020, 21, 2317-2324.	1.8	0
115	Nuclear Medicine Imaging in Chronic Inflammatory Diseases. , 2021, , 293-330.		0
116	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.6	0
117	Use of Positron Emission Tomography for Target Volume Definition. Current Radiopharmaceuticals, 2009, 2, 144-148.	0.8	0
118	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2636-2636.	1.4	0
119	Nuclear Medicine Imaging in Chronic Inflammatory Diseases. , 2013, , 289-331.		0
120	Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.. Journal of Clinical Oncology, 2014, 32, 8502-8502.	1.6	0
121	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. Blood, 2015, 126, 3919-3919.	1.4	0
122	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	1.4	0